bevacizumab + cyclophosphamide + imatinib

This is a combination regimen consisting of three agents: - **Bevacizumab** is a humanized monoclonal antibody that inhibits angiogenesis by binding to and neutralizing vascular endothelial growth factor A (VEGF-A), thereby preventing the growth of blood vessels that supply tumors. - **Cyclophosphamide** is an alkylating agent used as chemotherapy, which crosslinks DNA and leads to cell death, particularly in rapidly dividing cells. When administered at low, continuous ("metronomic") doses, it also exerts antiangiogenic effects. - **Imatinib** is a small molecule tyrosine kinase inhibitor targeting BCR-ABL, platelet-derived growth factor receptor (PDGFR), and c-KIT. It blocks signaling pathways involved in tumor proliferation and angiogenesis. The combination has been studied primarily in advanced solid malignancies such as colorectal cancer and other refractory cancers. The rationale for this regimen is to simultaneously inhibit tumor angiogenesis through VEGF blockade (bevacizumab), disrupt pericyte support via PDGFR inhibition (imatinib), and provide cytotoxic/antiangiogenic pressure with metronomic cyclophosphamide. Clinical trials have shown the combination to be safe and tolerable without significant drug interactions; some patients experienced prolonged stable disease[1][2].